Botox and Dysport are the two most widely used neurotoxin brands in aesthetic medicine, and the question of which one is better comes up in virtually every consultation room and training program. Both products contain botulinum toxin type A and work through the same fundamental mechanism: blocking acetylcholine release at the neuromuscular junction to temporarily relax targeted muscles. Yet they differ in formulation, diffusion characteristics, onset time, and unit dosing in ways that matter for both practitioners and patients.
This comparison examines every clinically relevant difference between Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) so that practitioners can make informed product selection decisions and patients can understand what they are receiving. We base our analysis on published clinical data, FDA labeling, and real-world practitioner experience from thousands of injectable training courses.
What Botox and Dysport Actually Are
Both Botox and Dysport are prescription medications derived from botulinum toxin type A, produced by the bacterium Clostridium botulinum. The toxin is purified, diluted, and formulated into an injectable product that temporarily paralyzes muscles by blocking nerve signals. Despite sharing the same active molecule, the two products are manufactured differently, resulting in distinct clinical profiles.
Botox (onabotulinumtoxinA) is manufactured by Allergan, now part of AbbVie. It was the first botulinum toxin approved by the FDA for cosmetic use in 2002 and remains the market leader with the most extensive clinical research portfolio. Botox is FDA-approved for glabellar lines, forehead lines, and lateral canthal lines (crow's feet), as well as numerous therapeutic indications including chronic migraine, cervical dystonia, overactive bladder, and severe axillary hyperhidrosis.
Dysport (abobotulinumtoxinA) is manufactured by Galderma, originally developed by Ipsen in Europe where it has been used since the late 1990s. Dysport received FDA approval for cosmetic use in moderate to severe glabellar lines in 2009. It differs from Botox in its protein complex size, manufacturing process, and reconstitution method, which contribute to its different diffusion and onset characteristics.
Side-by-Side Comparison Table
| Feature | Botox | Dysport |
|---|---|---|
| Generic Name | OnabotulinumtoxinA | AbobotulinumtoxinA |
| Manufacturer | Allergan (AbbVie) | Galderma |
| FDA Cosmetic Approval | 2002 | 2009 |
| Onset of Action | 3-5 days | 24-48 hours |
| Full Effect | 10-14 days | 10-14 days |
| Duration | 3-4 months | 3-4 months |
| Unit Conversion | 1 unit | 2.5-3 units |
| Typical Glabellar Dose | 20 units | 50 units |
| Diffusion / Spread | More localized | Greater spread |
| Protein Complex Size | ~900 kDa | ~500-900 kDa |
| Cost Per Unit (Avg.) | $10-$18 | $4-$8 |
| Avg. Treatment Cost | $300-$600 | $250-$550 |
Onset Time and Duration of Results
One of the most clinically significant differences between these two neurotoxins is onset speed. Dysport consistently demonstrates faster onset, with many patients reporting noticeable muscle relaxation within 24 to 48 hours after injection. Botox typically takes 3 to 5 days before patients see initial effects. This difference is attributed to Dysport's smaller protein complex size and greater diffusion rate, which allows it to bind to nerve terminals more rapidly.
For patients preparing for a specific event such as a wedding, photo shoot, or public appearance, Dysport's faster onset can be a meaningful advantage. Practitioners who understand this difference can make more targeted recommendations based on patient timelines.
In terms of duration, both products are comparable, with most patients experiencing results lasting 3 to 4 months. Some clinical studies have reported slightly shorter duration with Dysport in certain patients, while others show equivalent longevity. The practical difference in duration between the two products is minimal and often overshadowed by individual patient factors including metabolism, muscle mass, physical activity level, and treatment area.
Dosing and Unit Conversion
Understanding the dosing relationship between Botox and Dysport is critical for practitioners, especially when switching patients between products. The two products are not interchangeable unit for unit. The generally accepted conversion ratio is 1 unit of Botox to approximately 2.5 to 3 units of Dysport.
For the glabellar complex, the FDA-approved dose of Botox is 20 units across 5 injection sites, while the FDA-approved Dysport dose is 50 units across 5 injection sites. This 1:2.5 ratio holds reasonably well across most treatment areas, though experienced injectors may adjust based on individual patient anatomy, muscle mass, and desired outcomes.
It is essential to note that the unit measurements are product-specific and cannot be directly compared between brands. One unit of Botox is not pharmacologically equivalent to one unit of Dysport. This distinction is a fundamental patient safety concern that every injector must understand. Confusing the dosing between products can lead to significant under-treatment or over-treatment.
Spread and Diffusion Patterns
Dysport has a larger field of effect than Botox, meaning it diffuses further from the injection site. This difference in spread has practical clinical implications that can be either advantageous or disadvantageous depending on the treatment area.
When greater spread is beneficial: Large, flat muscles like the frontalis (forehead) can be treated with fewer injection points when using Dysport. The broader diffusion creates a more even effect across the muscle with less risk of untreated "stripe" patterns between injection sites. Some practitioners prefer Dysport specifically for the forehead for this reason.
When greater spread is a concern: In areas requiring precise, localized effect, Dysport's diffusion can increase the risk of affecting adjacent muscles. For example, treating crow's feet near the lower eyelid requires careful attention to prevent diffusion into the inferior oblique or lateral rectus muscles, which could cause diplopia (double vision). Similarly, treating the lateral brow requires precision to avoid unwanted brow ptosis.
Botox's more localized effect gives practitioners greater control in anatomically sensitive areas. This is why many experienced injectors maintain both products in their practice and select the one best suited for each specific treatment area and patient anatomy.
Cost Comparison
Price comparison between Botox and Dysport requires understanding the unit conversion. Dysport costs significantly less per unit, typically $4 to $8 per unit compared to Botox at $10 to $18 per unit. However, because Dysport requires approximately 2.5 to 3 times more units for equivalent effect, the total treatment cost ends up being similar.
For a typical forehead and glabellar treatment, the total cost ranges from approximately $300 to $600 for either product, depending on geographic location, practitioner experience, and practice setting. Some practices price Dysport slightly lower to differentiate or attract price-sensitive patients, while others charge the same effective rate for both products.
For practitioners, the wholesale acquisition cost per treatment is often similar between the two products as well. Manufacturer loyalty programs (Allergan's Alle for Botox, Galderma's Aspire for Dysport) provide rebates and patient rewards that can affect the effective cost for both the practice and the patient.
Which Is Right for Your Patients?
The honest answer is that neither product is universally superior. The best choice depends on several factors specific to each patient and treatment scenario. Here is a practical decision framework used by experienced injectors:
Consider Dysport when:
- Treating large, flat muscles (forehead) where broader diffusion is beneficial
- The patient wants faster onset (event in 2-3 days)
- The patient reports diminishing response to Botox (possible antibody development)
- The patient prefers a more natural, less "frozen" appearance in the forehead
Consider Botox when:
- Treating small, precise areas (crow's feet, brow lift, lip flip) where controlled placement is critical
- The patient has a proven history of good results with Botox
- Therapeutic applications (TMJ, migraine) where precise dosing and placement are well-established
- First-time patients who may feel more comfortable with the most recognized brand name
The Provider Perspective: Practice Considerations
Many successful aesthetic practices stock both Botox and Dysport. Having both options allows practitioners to select the product best suited for each treatment area and patient profile, which improves outcomes and demonstrates expertise. Patients increasingly appreciate having options and a provider who can explain why one product may be better for their specific needs.
From a business standpoint, carrying two neurotoxin brands provides leverage in supplier negotiations and protects against supply chain disruptions. It also allows the practice to participate in loyalty programs from both Allergan (Alle) and Galderma (Aspire), maximizing patient retention incentives.
Training on both products is essential for any injector who wants to offer comprehensive care. The Botox Certification Course at Facial Injectables covers both products extensively, including dosing conversion, product selection strategy, and hands-on injection with live patients using each formulation.
What the Clinical Evidence Shows
Multiple head-to-head studies have compared Botox and Dysport, and the overall evidence supports equivalent efficacy when appropriate conversion dosing is used. A 2019 meta-analysis published in the Journal of Cosmetic Dermatology found no statistically significant difference in patient satisfaction or treatment outcomes between the two products when dosed at the accepted 1:2.5 ratio.
Studies on onset time consistently favor Dysport, with several randomized controlled trials showing earlier onset by 1 to 3 days. This finding is supported by the product's pharmacologic profile, as the smaller protein complex facilitates faster receptor binding.
Regarding safety, both products carry the same FDA black box warning about the potential for distant spread of toxin effect. In practice, both products have excellent safety records when used by trained injectors at appropriate doses. The most common side effects for both products include injection site pain, headache, and temporary bruising.